Why the most feared antidepressants are making a quiet, evidence-based comeback
In short: Once sidelined due to dietary risks, monoamine oxidase inhibitors are regaining status as potent tools for treatment-resistant depression. Modern food safety standards have drastically reduced the dangers that once haunted these drugs, allowing clinicians to revisit them as highly effective options when standard therapies fail to provide relief.
Monoamine oxidase inhibitors (MAOIs) function by blocking enzymes that metabolize neurotransmitters like serotonin, dopamine, and norepinephrine. While classic, irreversible MAOIs—such as phenelzine, tranylcypromine, and isocarboxazid—were once the gold standard, their use declined following reports of hypertensive crises triggered by tyramine, a compound found in aged or fermented foods. However, modern food production, refrigeration, and hygiene have significantly lowered tyramine exposure, making the risk of serious blood pressure spikes substantially lower than in the early decades of their use.
Today, these drugs are primarily reserved for major depressive disorder that has not responded to other treatments, including SSRIs, SNRIs, or electroconvulsive therapy. Expert guidance suggests that classic MAOIs remain highly effective, particularly for atypical, melancholic, or treatment-resistant depression. While they require careful management of drug interactions—especially with serotonergic agents—modern prescribing protocols have moved away from blanket prohibitions. For instance, routine discontinuation before surgery is no longer standard practice; instead, clinicians now plan anesthesia around the patient's specific medication regimen.
The landscape of MAOIs is not monolithic. Selective MAO-B inhibitors like selegiline and rasagiline are widely used for Parkinson's disease, where they help preserve dopamine levels. Meanwhile, reversible inhibitors of MAO-A (RIMAs) offer a different safety profile with lower dietary risks. Even when using classic MAOIs, clinicians now employ nuanced strategies, such as using bridging agents or carefully selecting compatible antidepressants to manage side effects like insomnia or weight gain. By moving beyond outdated fears and focusing on precise pharmacological mechanisms, modern psychiatry is reclaiming these powerful agents for patients who have exhausted other options.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Monoamine oxidase inhibitor
- Also: www.mayoclinic.org — Monoamine oxidase inhibitors (MAOIs)
To cite this card, link to https://intellectplus.co.uk/app/science-monoamine-oxidase-inhibitor.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Human body & genes · More in Science · Latest · A–Z · All topics